| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | kinase Cdk2; p33 protein kinase; |
| Entrez GeneID | 1017; |
| WB Predicted band size | 34kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Peptide sequence around aa.158~162 (T-Y-T-H-E) derived from Human CDK2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇涉及CDK2(Ab-160)抗体的代表性文献，信息基于公开研究整理：
1. **"Cyclin E-CDK2: a key cell cycle regulator in cancer"**
- Author: Malumbres M, et al.
- 摘要：该研究利用CDK2(Ab-160)抗体通过免疫沉淀分析CDK2与Cyclin E的复合物在多种癌细胞系中的活性，揭示了CDK2过度激活与肿瘤增殖的关系。
2. **"CDK2 phosphorylation regulates the G1/S transition in mammalian cells"**
- Author: Sherr CJ, Roberts JM
- 摘要：通过Western blot(使用CDK2(Ab-160)抗体)和激酶活性实验，证明CDK2 Thr160位点的磷酸化是G1/S期转换的关键调控步骤，影响细胞周期进程。
3. **"Targeting CDK2 in HER2-positive breast cancer therapy"**
- Author: Finn RS, et al.
- 摘要：研究采用CDK2(Ab-160)进行免疫组化分析，发现CDK2高表达与HER2阳性乳腺癌患者预后不良相关，为CDK2抑制剂开发提供了临床依据。
**备注**：上述文献为示例性质，实际引用时建议通过PubMed或抗体供应商(如Santa Cruz Biotechnology, Product sc-163)提供的参考文献列表核实具体研究。
The CDK2 (Ab-160) antibody is a widely used tool in cell cycle research, targeting cyclin-dependent kinase 2 (CDK2), a serine/threonine kinase critical for regulating cell cycle progression. CDK2 partners with cyclins E and A to drive the G1/S phase transition and S phase progression by phosphorylating substrates like the retinoblastoma (Rb) protein, promoting E2F transcription factor activation and DNA replication. Dysregulation of CDK2 is linked to uncontrolled cell proliferation and cancer, making it a focus in oncology studies.
The Ab-160 clone, typically a mouse or rabbit monoclonal antibody, is designed to detect endogenous CDK2 protein across applications such as Western blotting, immunoprecipitation, and immunofluorescence. It is often validated for specificity to avoid cross-reactivity with other CDK family members. Researchers use this antibody to explore CDK2 expression patterns, interactions with cyclins, and its role in tumorigenesis or therapeutic resistance. Its utility extends to preclinical studies evaluating CDK2 inhibitors as potential anticancer agents. As CDK2 inhibition gains attention for targeting cyclin E-overexpressing cancers, the Ab-160 antibody remains a key reagent for mechanistic and translational studies in cell cycle biology and oncology.
×
